This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
cancer: Archive
Zacks Initiates Coverage of Precipio With Outperform Recommendation
by Debanjana Dey
Discover why Zacks rates Precipio as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore PRPO's approaching breakeven milestones, financial health, and market positioning in the cancer diagnostics space.
PRPONegative Net Change
cancer medical
Bull of the Day: NVIDIA (NVDA)
by Kevin Cook
After Computex, I raised my price target to $200 because Wall Street still has no idea what's coming
NVDANegative Net Change
aerospace alt-energy artificial-intelligence automation biotechnology cancer cloud-computing cybersecurity gene-therapy genomics oncology-screening semiconductor smart-health
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.
GSKNegative Net Change PFENegative Net Change MRKPositive Net Change MRNANegative Net Change
biotechs cancer medical messenger-rna pharmaceuticals vaccines
Top Medical Stocks to Buy for Growth & Performance
by Shaun Pruitt
The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.
HAEPositive Net Change HALONegative Net Change NBIXPositive Net Change
cancer earnings hospitals investing medical medical-devices oncology-screening pharmaceuticals
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
by Kinjel Shah
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
BMYNegative Net Change PFENegative Net Change BNTXPositive Net Change
cancer oncology-screening
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
JNJPositive Net Change PFENegative Net Change NVOPositive Net Change LLYPositive Net Change
biotechnology cancer gene-therapy
3 Attractive Medical Stocks to Buy After Earnings
by Shaun Pruitt
Following their favorable quarterly results this week here are three intriguing healthcare stocks that investors will want to consider.
MCKNegative Net Change EXELPositive Net Change EHCPositive Net Change
biotechnology cancer earnings hospitals investing medical pharmaceuticals
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High
by Bryan Hayes
As investors, our job isn't to predict an unknowable future.
NVSPositive Net Change LLYPositive Net Change
artificial-intelligence cancer earnings investing large-cap oncology-screening pharmaceuticals semiconductor tech-stocks
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite
NEOPositive Net Change NTRANegative Net Change GHPositive Net Change
cancer genetic-testing genomics oncology-screening smart-health
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Contracting margins, antitrust over GRAIL, and the Icahn invasion all crash estimates and shares
ILMNNegative Net Change
biotechnology cancer genetic-testing genomics oncology-screening smart-health